Replicel 2012
I had just received an email today from Replicel to update me on their testing phases.
"April 3, 2012
By RepliCel on April 3, 2012
VANCOUVER, BC – April 3, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to report that all 19 subjects have completed their six-month post injection follow-up visit and the company remains on schedule to release the initial review of efficacy results in April 2012. The data collected from the first six months following injection will be used for assessment of the primary safety and secondary safety and efficacy endpoints for the TS001-2009 clinical trial.
In March and throughout the month of April 2012, the TS001-2009 study team will be retrieving data from the study centre in Tbilisi, Georgia and sending it to an independent clinical research organization data management team in Munich, Germany. Once received, it is entered into a database and reviewed for any anomalies in the collected data. These anomalies are then sent to the study centre for clarification and/or correction. These standard reviews ensure accuracy in the information collected for the study…"
|
Linear Mode
